Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Diamyd Medical Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Diamyd Medical şirketinin toplam hissedar öz sermayesi SEK195.4M ve toplam borcu SEK0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla SEK248.2M ve SEK52.8M dir.

Anahtar bilgiler

Borç/özkaynak oranı

SEK 0

Borç

Faiz karşılama oranı	n/a
Nakit	SEK 132.37m
Eşitlik	SEK 145.92m
Toplam yükümlülükler	SEK 71.12m
Toplam varlıklar	SEK 217.04m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: DMN 'nin kısa vadeli varlıkları ( SEK183.4M ) kısa vadeli yükümlülüklerini ( SEK20.7M ) aşıyor.

Uzun Vadeli Yükümlülükler: DMN şirketinin kısa vadeli varlıkları ( SEK183.4M ) uzun vadeli yükümlülüklerini ( SEK32.1M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: DMN borçsuzdur.

Borcun Azaltılması: DMN son 5 yıldır borcu bulunmamaktadır.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: DMN şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: DMN un, serbest nakit akışı her yıl % 29.5 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Diamyd Medical Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Full year 2024 earnings released: kr1.52 loss per share (vs kr1.48 loss in FY 2023)

Diamyd Medical AB (publ) to Report Q1, 2025 Results on Jan 29, 2025

Diamyd Medical to Pursue Accelerated Approval Pathway for Type 1 Diabetes Precision Medicine

Diamyd Medical Announces Positive Interim Analysis Results for Phase 3 Trial in Type 1 Diabetes

New major risk - Share price stability

Third quarter 2024 earnings released

Diamyd Medical AB (publ) to Report Q4, 2024 Results on Nov 14, 2024

Diamyd Medical AB (publ) Updates on the Registrational Phase 3 Trial

Independent Chairman recently sold €56k worth of stock

Recruitment Milestone Reaches in Diamyd® Phase 3 Trial

Second quarter 2024 earnings released

New major risk - Share price stability

First quarter 2024 earnings released

In-Depth Analysis of Diamyd Medical AB (publ)'s Phase II Trial Further Supports Value of Presented Insulin Production

Diamyd Medical's Precision Medicine Patent for the Prevention and Treatment of Autoimmune Diabetes Granted in South Korea

Diamyd Medical AB (Publ) Elects Karin Rosén as A New Member of the Board

Diamyd Medical AB (publ) to Report Fiscal Year 2023 Results on Nov 30, 2023

Diamyd Medical AB (publ) has completed a Composite Units Offering in the amount of SEK 69.834709 million.

Diamyd Medical AB (Publ) Announces Follow-Up Study Recommends Diamyd to Offer Advantages in Delivering Type 1 Diabetes Onset

Diamyd Medical AB (publ) Announces Preliminary Results from Booster Trial with Diamyd Provide Additional Support for Intralymphatic Injection

Diamyd Medical AB (publ) to Report Q2, 2024 Results on Mar 27, 2024

Full year 2023 earnings released: kr1.30 loss per share (vs kr1.35 loss in FY 2022)

Diamyd Medical AB (Publ) Announces Changes of the Board

Diamyd Medical AB (Publ) Announces Registrational Phase III Trial in Type 1 Diabetes with Diamyd Expands to the US

New minor risk - Shareholder dilution

Diamyd Medical AB (publ), Annual General Meeting, Nov 30, 2023

Third quarter 2023 earnings released

Second quarter 2023 earnings released

Diamyd Medical Receives Patent Protection in the US and Japan for Gaba Formulation Remygen

First quarter 2023 earnings released: kr0.43 loss per share (vs kr0.52 loss in 1Q 2022)

Diamyd Medical Precision Medicine Patent for Prevention and Treatment of Autoimmune Diabetes to Be Granted in Eurasia

Diamyd Medical AB (Publ) Announces US Partial Clinical Hold on Diamyd® Phase III Trial Lifted by the FDA

Full year 2022 earnings released: kr1.35 loss per share (vs kr0.86 profit in FY 2021)

All Patients in DIAGNODE-B Have Received an Additional (Booster) Injection of Diamyd

Diamyd Medical AB (publ) to Report Q3, 2023 Results on Jun 28, 2023

Third quarter 2022 earnings released

Diamyd Medical AB (publ), Annual General Meeting, Dec 01, 2022

Diamyd Medical AB (publ) Announces First Patient Enrolled in its Phase III Trial DIAGNODE-3

Director recently sold €99k worth of stock

Diamyd Medical AB Announces New Clinical Trial Will Evaluate an Additional Injection (Booster) with Diamyd

Second quarter 2022 earnings released

Clinical Trial in Type 1 Diabetes with Diamyd Medical's Remygen Is Fully Recruited

Diamyd Medical Proceeds with Initiation of Type 1 Diabetes Phase III Trial in Europe

First quarter 2022 earnings: Revenues miss analyst expectations

Diamyd Medical AB Patent for Intralymphatic Injection of GAD in Autoimmune Diabetes to Be Granted in China

Diamyd Medical Announces Australia Grants as the First Region Diamyd Medical A Broadening of A Patent for Intralymphatic Injection of Antigens in Autoimmune Diabetes

Director recently sold €358k worth of stock

Investor sentiment deteriorated over the past week

Diamyd Medical Pauses Start of Phase III Trial

Full year 2021 earnings released: EPS kr0.86 (vs kr0.14 in FY 2020)

Investor sentiment deteriorated over the past week

Full year 2021 earnings released: EPS kr0.84 (vs kr0.14 in FY 2020)

Investor sentiment deteriorated over the past week

Diamyd Medical AB Receives First Regulatory Approval to Start the Phase III Trial DIAGNODE-3 with the Diabetes Vaccine Diamyd®

Investor sentiment improved over the past week

Third quarter 2021 earnings released

Diamyd Medical AB (Publ) Announces 24-Month Follow-Up of Phase IIb Diamyd® Clinical Trial Indicates Continued Similar Progression After 15 Months

the 24-Month Follow-Up of DIAGNODE-2 with the Diabetes Vaccine Diamyd® Will Be Presented in Early July

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released

Diamyd Medical AB (publ) Announces Update on the design of a Phase III Precision Medicine trial with the Diabetes Vaccine Diamyd®

Investor sentiment improved over the past week

New 90-day high: €3.62

Investor sentiment improved over the past week

New 90-day low: €2.46

Director recently sold €116k worth of stock

New 90-day low: €2.73

Diamyd Medical AB Announces Positive Safety Evaluation of Remygen® in High Dose and in Combination with Alprazolam Gives the Go-Ahead for the Continuation of the Trial

Meta-Analysis Updated with DIAGNODE-2 Results Provides Further Support for A Precision Medicine Approach Using Diamyd Medical

Diamyd Medical and Critical Path Institute Announce Data Sharing Collaboration to Develop Advanced Drug Development Tools in Type 1 Diabetes

Insider recently sold €34k worth of stock

Diamyd Medical AB (publ) Announces Operational Update About the Diabetes Vaccine Diamyd

Diamyd Medical AB (publ) to Report Fiscal Year 2021 Results on Oct 06, 2021

New 90-day high - €4.39

New 90-day high - €2.52